Frank Maldarelli1. 1. HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. fmalli@mail.nih.gov
Abstract
PURPOSE OF REVIEW: HIV infection is controlled but not cured by combination antiretroviral therapy. HIV may persist for a number of reasons, including ongoing cycles of HIV infection or viral persistence as latent, or HIV replication in long-lived cells containing HIV proviruses. Therapeutic consequences of these alternative mechanisms are significant and distinct. If ongoing replication remains during current antiretroviral therapy, then improvements in potency will be useful in eradication strategies. Alternatively, long-lived cells with integrated proviruses will not be affected by improvements in therapy directed against active infection, and new strategies will be necessary for HIV eradication. Technologic advances have made it possible to carry out a series of drug intensification protocols in well suppressed patients; these and other analyses for HIV replication have been useful to elucidate the nature of HIV persistence on therapy. RECENT FINDINGS: A number of clinical studies intensifying antiretroviral therapy carried out in the last several years have yielded new findings regarding the ability to detect the presence of ongoing replication. Decreases in persistent viremia have not been consistently detected in individuals on potent combination antiretroviral therapy. Evidence for persistent replication has been reported in patients using sensitive assays of cell-associated HIV. SUMMARY: HIV viremia persists despite combination antiretroviral therapy. Antiretroviral drug intensification does not lower the level of HIV measured in plasma, suggesting current therapy arrests active virus replication. HIV eradication will most likely require therapy in addition to potent antiretroviral therapy.
PURPOSE OF REVIEW: HIV infection is controlled but not cured by combination antiretroviral therapy. HIV may persist for a number of reasons, including ongoing cycles of HIV infection or viral persistence as latent, or HIV replication in long-lived cells containing HIV proviruses. Therapeutic consequences of these alternative mechanisms are significant and distinct. If ongoing replication remains during current antiretroviral therapy, then improvements in potency will be useful in eradication strategies. Alternatively, long-lived cells with integrated proviruses will not be affected by improvements in therapy directed against active infection, and new strategies will be necessary for HIV eradication. Technologic advances have made it possible to carry out a series of drug intensification protocols in well suppressed patients; these and other analyses for HIV replication have been useful to elucidate the nature of HIV persistence on therapy. RECENT FINDINGS: A number of clinical studies intensifying antiretroviral therapy carried out in the last several years have yielded new findings regarding the ability to detect the presence of ongoing replication. Decreases in persistent viremia have not been consistently detected in individuals on potent combination antiretroviral therapy. Evidence for persistent replication has been reported in patients using sensitive assays of cell-associated HIV. SUMMARY:HIV viremia persists despite combination antiretroviral therapy. Antiretroviral drug intensification does not lower the level of HIV measured in plasma, suggesting current therapy arrests active virus replication. HIV eradication will most likely require therapy in addition to potent antiretroviral therapy.
Authors: Jennifer L McDermott; Isabella Martini; Davide Ferrari; Francesca Bertolotti; Claudio Giacomazzi; Giuseppe Murdaca; Francesco Puppo; Francesco Indiveri; Oliviero E Varnier Journal: J Clin Microbiol Date: 2005-10 Impact factor: 5.948
Authors: Aylin Yilmaz; Chris Verhofstede; Antonio D'Avolio; Victoria Watson; Lars Hagberg; Dietmar Fuchs; Bo Svennerholm; Magnus Gisslén Journal: J Acquir Immune Defic Syndr Date: 2010-12-15 Impact factor: 3.731
Authors: D McMahon; J Jones; A Wiegand; S J Gange; M Kearney; S Palmer; S McNulty; J A Metcalf; E Acosta; C Rehm; J M Coffin; J W Mellors; F Maldarelli Journal: Clin Infect Dis Date: 2010-03-15 Impact factor: 9.079
Authors: Diane V Havlir; Matthew C Strain; Mario Clerici; Caroline Ignacio; Daria Trabattoni; Pasquale Ferrante; Joseph K Wong Journal: J Virol Date: 2003-10 Impact factor: 5.103
Authors: Martin Markowitz; Bach-Yen Nguyen; Eduardo Gotuzzo; Fernando Mendo; Winai Ratanasuwan; Colin Kovacs; Guillermo Prada; Javier O Morales-Ramirez; Clyde S Crumpacker; Robin D Isaacs; Lucinda R Gilde; Hong Wan; Michael D Miller; Larissa A Wenning; Hedy Teppler Journal: J Acquir Immune Defic Syndr Date: 2007-10-01 Impact factor: 3.731
Authors: J B Dinoso; S Y Kim; A M Wiegand; S E Palmer; S J Gange; L Cranmer; A O'Shea; M Callender; A Spivak; T Brennan; M F Kearney; M A Proschan; J M Mican; C A Rehm; J M Coffin; J W Mellors; R F Siliciano; F Maldarelli Journal: Proc Natl Acad Sci U S A Date: 2009-05-22 Impact factor: 11.205
Authors: Joseph P Casazza; Kathryn A Bowman; Selorm Adzaku; Emily C Smith; Mary E Enama; Robert T Bailer; David A Price; Emma Gostick; Ingelise J Gordon; David R Ambrozak; Martha C Nason; Mario Roederer; Charla A Andrews; Frank M Maldarelli; Ann Wiegand; Mary F Kearney; Deborah Persaud; Carrie Ziemniak; Raphael Gottardo; Julie E Ledgerwood; Barney S Graham; Richard A Koup Journal: J Infect Dis Date: 2013-03-12 Impact factor: 5.226
Authors: Paul W Denton; Rikke Olesen; Shailesh K Choudhary; Nancy M Archin; Angela Wahl; Michael D Swanson; Morgan Chateau; Tomonori Nochi; John F Krisko; Rae Ann Spagnuolo; David M Margolis; J Victor Garcia Journal: J Virol Date: 2011-10-19 Impact factor: 5.103
Authors: Rutao Luo; E Fabian Cardozo; Michael J Piovoso; Hulin Wu; Maria J Buzon; Javier Martinez-Picado; Ryan Zurakowski Journal: J R Soc Interface Date: 2013-05-08 Impact factor: 4.118